Save the date!

The Center for RNA Biomedicine at the University of Michigan, in partnership with the Society for RNA Therapeutics, proudly invites you to the 2025 RNA Symposium. Taking place from Thursday, March 6 to Saturday, March 8, 2025, this premier event will convene thought leaders and pioneering researchers in the field of RNA science and biomedicine.

For more information, please visit us at: 2025 Symposium - Center for RNA Biomedicine (umich.edu)

We are thrilled to announce the appointment of Dr. Drew Weissman to the Board of Directors of the Society for RNA Therapeutics! Dr. Weissman's pioneering work in the development of mRNA vaccine technology has revolutionized the field of medicine, offering new hope in the fight against infectious diseases, cancer, and beyond. His expertise and visionary leadership in RNA therapeutics will undoubtedly guide our society towards groundbreaking advancements and achievements. Please join us in extending a warm welcome to Dr. Weissman, as we look forward to an exciting future together, pushing the boundaries of science and improving patient care worldwide.

As RNA therapeutics become more prevalent we will require more robust and reliable methods for their QC/QA. New work from the Mercer Lab shows that nanopore sequencing can be quite useful for quantifying homogeneity of mRNA therapeutics!

 

https://www.nature.com/articles/s41467-023-41354-y#Ack1

We are glad to share this article on the pathway to approval for Tofersen; the first intrathecally delivered RNase H ASO to receive FDA approval and the second approved intrathecal ASO. 

https://pubmed.ncbi.nlm.nih.gov/37581487/

 

As RNA therapeutics become more prevalent we will require more robust and reliable methods for their QC/QA. New work from the Mercer Lab shows that nanopore sequencing can be quite useful for quantifying homogeneity of mRNA therapeutics!

https://www.nature.com/articles/s41467-023-41354-y#Ack1

We are thrilled to share that the faculty at MIT is spearheading a groundbreaking 3-year research program in collaboration with the FDA, with a remarkable $82 million investment. Their ambitious goal is to design the world's first fully integrated, continuous mRNA manufacturing platform.

This initiative represents a significant leap forward in the field of mRNA technology, paving the way for enhanced efficiency, scalability, and accessibility in vaccine production and therapeutics development. The potential impact on global health is immense!

As we continue to witness the remarkable power of mRNA in combating diseases, this program's vision aligns perfectly with the urgent need to accelerate manufacturing capabilities and streamline processes. By leveraging the expertise of MIT's renowned faculty, we are poised to revolutionize the way mRNA is produced and delivered.

Kudos to the visionary leaders, brilliant researchers, and dedicated teams at MIT for undertaking this groundbreaking endeavor. Your relentless pursuit of innovation and commitment to improving human health are truly inspiring!

Stay tuned for exciting updates as we witness the progress and discoveries that will undoubtedly emerge from this program. Together, let's celebrate the incredible potential of science and collaboration!

https://news.mit.edu/2023/mit-researchers-lead-new-center-mrna-manufacturing-0713

#SRT #MITResearch #mRNAInnovation #HealthcareAdvancements #CollaborativeScience

As Jim Stallard said, "Messenger RNA (mRNA) vaccines may be the hottest thing in science now....."

Read his article... https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out

Global Experts Launch New Medical Society to Promote Research, Education and Development in RNA Therapeutics

RNA therapeutics are changing the way medicine is developed and delivered. The Society for RNA Therapeutics is led by an international group of scientists and physicians and is dedicated to serving scientists, clinicians, patient groups, policymakers and the broader public.

WASHINGTON (PRWEB) April 10, 2023

The Society for RNA Therapeutics is pleased to announce the members of its charter board of directors. The mission of the newly formed nonprofit scientific society is to promote translational research and development of RNA therapeutics to improve global health. RNA therapeutics have the potential to revolutionize numerous potential medical applications, including treatment of genetic diseases, cancer treatment, vaccines, regenerative medicine, and rare diseases.

“RNA therapeutics are changing the way medicine is developed and delivered,” said John P. Cooke, M.D., Ph.D., Founder and President of the Society for RNA Therapeutics. “The Society for RNA Therapeutics is led by an international group of scientists and physicians and is dedicated to serving scientists, clinicians, patient groups, policymakers and the broader public. Together, the Society will promote research, education and share key advances in this rapidly emerging field of medicine.”

The charter members of the Society for RNA Therapeutics Board of Directors are:

President: John P. Cooke, M.D., Ph.D.
Medical Director, Center for RNA Therapeutics
Chief Translational Officer, Houston Methodist Academic Institute

Vice President: Bruce A. Sullenger, Ph.D.
Joseph and Dorothy Beard Professor
Department of Surgery, Duke University

Secretary-Treasurer: Lior Zangi, Ph.D.
Associate Professor, Genetics and Genomic Sciences
Icahn School of Medicine at Mount Sinai

Annemieke Aartsma-Rus, Ph.DD.
Professor of Translational Genetics
Department of Human Genetics
Leiden University Medical Center

Virginia Arechavala-Gomeza, Ph.D.
Ikerbasque Research Professor
Group Leader, Neuromuscular Disorders,
Biocruces Bizkaia Health Research Institute

Maria Carmo-Fonseca, MD, Ph.D.
Immediate Past President, RNA Society
Group Leader, Instituto de Medicina Molecular

Pieter R. Cullis, Ph.D., FRSC, FNAI (USA)
Professor, Department of Biochemistry and Molecular Biology - UBC
Nanomedicines Research Group
Founding Director, Centre for Drug Research and Development
Founding Scientific Director and CEO, NanoMedicines Innovation Network

Michelle L. Hastings, Ph.D.
Director, Center for Genetic Diseases
Professor and Vice-Chair, Cell Biology and Anatomy
Chicago Medical School
Rosalind Franklin University of Medicine and Science

Amanda E. Hargrove, Ph.D.
Associate Professor of Chemistry
Duke University

Adrian Krainer, Ph.D.
St. Giles Foundation Professor
Cancer Center Deputy Director of Research
Cold Spring Harbor Laboratory

Prof. Dan Peer, Ph.D.
Director, Laboratory of Precision NanoMedicine
Shmunis School for Biomedicine and Cancer Research
Tel Aviv University
Department of Cell Research and Immunology, Dept of Cell Research & Immunology

Anna Marie Pyle Ph.D.
Sterling Professor of Molecular, Cellular and Developmental Biology and Professor of Chemistry
Yale University

John J. Rossi, Ph.D.
Professor and Director, Center for RNA Biology and Therapeutics
Dean Emeritus, Irell & Manella Graduate School of Biological Sciences
City of Hope

Timothy Yu, M.D., Ph.D.
Attending Physician, Division of Genetics and Genomics
Associate Professor of Pediatrics, Harvard Medical School
Boston Children’s Hospital
Division of Genetics and Genomics

The Society for RNA Therapeutics is a global network with goals that impact all aspects of RNA therapeutics:

• Support translational research and development of RNA therapeutics
• Develop standards for RNA manufacturing and guidelines for clinical trials
• Facilitate public-private-regulatory partnerships and to advocate for accessible RNA therapeutics for all patients
• Provide public and professional education and develop training guidelines
• Advocate for patients with diseases amenable to RNA therapies
• Develop clinical best practices in RNA therapeutics
• Support early career and professional development
• Advocate accessibility to RNA therapeutics for low and middle income countries for the enhancement of global health

The Society for RNA Therapeutics also launched its website that provides information about the organization’s goals, news about and RNA therapeutics, becoming a member, sponsorship and future events. Read more about the Society for RNA Therapeutics on the newly released website, http://www.srnat.org.

In 2022, the Biopharma industry saw groundbreaking advances in several areas like - RNA therapeutics, gene editing, ADCs, LAG-3 inhibitors, and TYK-2 inhibitors

AHMEDABAD, GUJARAT, INDIA, March 14, 2023
/EINPresswire.com/ -- “Top 10 Life sciences trends in 2022”, a research report released recently by Healthark Insights focuses on the top trends that are shaping the future of the biopharma industry, amongst various innovations that are happening in the life sciences domain.

The Healthark Insights team tracked and captured 100+ significant trends in the life sciences and biopharma industry in 2022.

Biopharma is set to witness one of the biggest patent cliffs with several blockbuster drugs undergoing loss of exclusivity from 2023-2028, totaling around $200B in revenue loss” — Dr. Purav Gandhi 

We gathered key information for each trend such as focus area, novelty, lucrativeness, market interest, commercialization, etc. to understand the larger impact potential of each trend. Each trend was then given a weightage and rating based on two key criteria – (i) impact on the future of health and, (ii) ease of commercialization. The top 10 trends were identified on their scores and were analyzed further to understand their potential to bring about disruption in the Life Sciences industry.

Several emerging and novel therapies buzzed throughout the year 2022. RNA therapeutics, Gene editing, and ADC therapeutics garnered a lot of attention from biopharma, whereas novel therapies such as LAG-3 inhibitors and TYK-2 inhibitors came into the spotlight with first-in-class approvals in 2022.

RNA therapeutics with 850+ assets in the clinical pipeline in 2022 and increasing collaborations between big pharma and biotech have become an attractive class for the industry. Gene editing, on the other hand, gained sudden popularity after the pandemic with pouring investments and intense pipelines across a range of therapy areas. Antibody-drug conjugates (ADC) famously known as the magic bullet in cancer, after two decades of trial and error in R&D, have once again picked up interest from the industry and are poised to deliver a plethora of targeted drugs to treat a wide range of tumor types.

TYK2 inhibitors, a new class from the JAK family, is a promising avenue in immunology and have drawn the biopharma sector’s eyeballs due to their better safety profile and the possibility of oral RoA. LAG-3 inhibitors are the potential next big checkpoint inhibitor target filling a complex role in the immune system. There are heavy clinical pipelines with 165 active clinical trials on 38 drugs that are targeting LAG-3. BMS is leading the race in both categories with its first product approvals in these novel categories - Sotyktu as TYK-2 inhibitor and Opdualag as LAG-3 inhibitor.

Biopharma is set to witness one of the biggest patent cliffs with several blockbuster drugs undergoing loss of exclusivity from 2023-2028, totaling around >$200B in revenue loss. Due to this, a biosimilar boom is expected in this decade, especially driven by biosimilars for Humira. Regulatory support is also increasing in this area, with CMS permitting the substitution of interchangeable biosimilars. Congress’ Biosimilar user fee act (BsUFA) reauthorization will increase access and adoption of biosimilars.

It is also important to note that despite relaxation from covid-19 pandemic, the interest in decentralized clinical trials (DCT) not only persists among the biopharma but has also increased globally. Takeda leads the DCT trials suite with 33% of its total clinical trials being DCT in 2022.

You can read more of such interesting insights on “Top 10 Life sciences trends of 2022” by visiting the Healthark Insights website.

About Healthark Insights Top 10 Research Report Series
Healthark Insights annually tracks the top events and trends in the healthcare and life sciences industry and publishes five reports at the end of each year summarizing the top 10 trends in the healthcare industry, life sciences industry, health tech, the top 10 innovations, and top 10 mergers & acquisitions, with an objective of summarizing the key events and industry-shaping forces during the previous year and shares a viewpoint on how the sector will evolve in the coming year.

About Healthark
Insights Healthark Insights is a global management consulting firm developed by a team of experts from diverse fields such as consulting, pharma, medicine, medical devices, digital health, public health, and management with a common vision to cater to the healthcare and life sciences industry, along with a relentless focus on delivering executable solutions.

Healthark Insights team helps customers make critical decisions every day through expertise that combines deep domain knowledge, rigorous research, and analysis, understanding of markets, technology, and experience. With the right experience and expertise, the team not only provides insights but also works closely with clients to execute the strategy that they have helped develop.

Purav Gandhi
Healthark Wellness Solutions LLP
+91 91600 01292
email us here
Visit us on social media:
Twitter
LinkedIn
YouTube

Top 10 Lifesciences Trends in 2022 - A video snapshot by Healthark Insights